Liraglutide 3.0  mg in the treatment of adults with obesity and prediabetes using real‐world UK data: A clinical evaluation of a multi‐ethnic population

Graphical abstract of study findings. SummaryUK guidelines recommend liraglutide 3.0  mg in adults treated within specialist weight management services with BMI ≥35 kg/m2, prediabetes and high cardiovascular disease risk. We aimed to clinically evaluate liraglutide 3.0  mg in specialist weight management services. We evaluated liraglutide 3.0 mg in weight management services at Guys and St Thomas' NHS Foundation Trust. Objective body weight (BW) was measured at baseline and 4 months, allowing classification as ‘responders’ (≥5% BW reduction) and ‘non -responders’ (<5% BW reduction). One hundred and twenty-one patients were evaluated. At 4  months, 76.0% attended follow-up (82.6% responders, 17.4% non-responders); BW (−8.6 kg, 95%CI:-9.8, −7.4 kg), BMI (−3.2 kg/m2, 95%CI: −3.6, −2.8) and %-BW (−6.6%, IQR: −8.8%, −5.2%) significantly reduced. In responders, HbA1c reduced by −5.0 mmol/mol (IQR: −7.0. −4.0 mmol/mol). In responders BW continued to reduce up to 12 months (4 m: −10.2 kg,p <  .0001; 6 m: −15.6 kg,p <  .0001; 9 m: −16.5 kg,p <  .0001; 12 m: −16.7 kg,p <  .01). Those of Black African and Caribbean ethnicity experienced less BW loss than those of white ethnicity (4.12 kg,p = .017) and had a greater attrition rate. In adults with obesity and prediabetes who are treated within specialist weight management services, liraglutide 3.0 mg reduces BW and HbA1...
Source: Clinical Obesity - Category: Eating Disorders & Weight Management Authors: Tags: ORIGINAL RESEARCH Source Type: research